Intelligent Bio Solutions Surges 238% on Strong Earnings
    Intelligent Bio Solutions Surges 238% on Strong Earnings
    PRISM Biotech

    February 09, 2024 - by Catie Corcoran

    Intelligent Bio Solutions Surges 238% on Strong Earnings

    09 February 2024

    New York, February 09, 2024 - PRISM MarketView - Shares in rapid test solutions company, Intelligent Bio Solutions (Nasdaq: INBS), surged nearly 240% in intraday trading on Friday after the company reported its financial results for fiscal second quarter and six months ended December 31, 2023, and provided a business update. Intelligent Bio Solutions is leading the PRISM MarketView Emerging MedDevices Index today.

    Small Cap Medical Device Stocks - Prism MarketView

    The PRISM Emerging MedDevices Index tracks small/micro-cap stocks which are developing or marketing any type of medical device. Please note the default display

    Read More

    Intelligent Bio Solutions Inc. - Prism MarketView

    Intelligent Bio Solutions Inc. - Prism MarketView

    Intelligent Bio Solutions is on a mission to redefine the approach to testing and deliver pain-free, accessible solutions that drive transformative change and

    Read More

    Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

    Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights

    - Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 - - Expanded into New Zealand market and increased market share in existing regions - NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its financial results for fiscal second quarter and six months end

    Read More

    The company’s year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023.

    “Our revenue growth numbers are indicative of an increasing need for an efficient drug screening solution that reduces risk, saves costs, and promotes productivity. We aim to sustain this rapid trajectory throughout 2024.”

    Intelligent Bio Solutions President and Chief Executive Officer, Harry Simeonidis

    Highlights
    Intelligent Bio Solutions entered the New Zealand market in 2023, a key milestone in the Company’s Asia Pacific expansion strategy.
    Strong increases in revenue are due to the acquisition of Intelligent Fingerprinting Ltd in October 2022, and growth of the company’s Asia Pacific business, Intelligent Bio Solutions (APAC) Pty Ltd, in addition to expansion into new regions and growth of the company in existing markets and regions.
    In October 2023, Intelligent Bio Solutions raised approximately $4.38 million via a registered underwritten public offering of the company’s securities, and the company ended the quarter with cash and cash equivalents of approximately $1.12 million.
    About Intelligent Bio Solutions Inc.
    Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company’s biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company’s current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.
    PRISM MarketView does not provide investment advice.
    Media Contact
    Company Name: Prism MarketView
    Email: info@prismmarketview.com
    Phone: 646-863-6341
    Website: https://prismmarketview.com
    To see this content properly accept cookies.
    PRISM MarketView Social Media
    To see this content properly accept cookies.
    To see this content properly accept cookies.
    Related Stories
    PRISM Biotech
    A Good Night’s Sleep: Tonix Phase 3 Results Offer Hope for Fibromyalgia Sufferers

    New York, February 12, 2024 - PRISM MarketView -  Tonix Pharmaceuticals (Nasdaq: TNXP) is offering new hope to the 6 – 12 million Americans living with fibromyalgia with a potential new frontline treatment that has a completely new mechanism of action, relative to the th...

    12 February 2024

    PRISM Biotech
    FDA Clearance for T2 Biosystems Diagnostic Panel

    New York, February 12, 2024 - PRISM MarketView - T2 Biosystems, Inc. (Nasdaq: TTOO) has received 510(k) clearance from the FDA for its expanded T2Bacteria® Panel, adding the capability to detect another bacterial species, Acinetobacter baumannii (A. baumannii), to its pa...

    12 February 2024

    PRISM View
    SunPower Secures Over $300M in Financing to Fuel Expansion of Residential Solar and Storage Solutions

    New York, February 23, 2024 - PRISM MarketView - SunPower Corp. (Nasdaq: SPWR), an emerging player in the residential solar technology and energy services sector, has successfully secured over $300 million in project financing commitments. This funding, sourced from Apol...

    23 February 2024

    PRISM View
    PRISM Med Device Index Tech Company Vapotherm, Inc. (VAPO) Announces Fourth Quarter Earnings

    New York, February 23, 2024 - PRISM MarketView - PRISM Emerging Med Device Index tech company Vapotherm (VAPO) specializes in the development and commercialization of innovative respiratory support devices. The company is known for its high-flow therapy systems, which de...

    23 February 2024

    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.